Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

The Ohio State University

Columbus, Ohio

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) strives to create a cancer-free world, one person, one discovery at a time through research that translates to innovative and highly targeted patient care.

The OSUCCC – James is the only cancer program in the United States that features a National Cancer Institute (NCI)–designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities.

At the Forefront of Research

The OSUCCC – James is one of only 51 NCI-designated comprehensive cancer centers in the nation, a designation it has maintained through competitive renewal since 1976. After its most recent NCI site review, the cancer center earned the NCI’s highest ranking, “exceptional,” for the third consecutive time and received a five-year NCI cancer center support grant.

At Ohio State, more than 330 cancer researchers and their teams from 11 of the university’s 15 colleges work collaboratively across multiple disciplines to improve the effectiveness of cancer prevention, diagnosis and treatment. Each scientist is a member of one of five interdisciplinary research programs: Cancer Control, Translational Therapeutics, Cancer Biology, Molecular Carcinogenesis and Chemoprevention, and Leukemia Research.

The OSUCCC – James also recently established a Pelotonia Institute for Immuno-Oncology (PIIO)—a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels, from prevention to treatment and survivorship. The PIIO, which complements the OSUCCC – James’ pursuit of precision cancer medicine-driven therapies, has developed a strategic plan and recruited many scientists and staff members with expertise ranging from development of cancer vaccines to bioinformatic and statistical modeling for high-throughput immunogenomic screening. These scientists have brought the total number of researchers working on immuno-oncology approaches to clinical trials at the OSUCCC – James to over 60.

The PIIO plans to open up to 130 immuno-oncology clinical trials over the next five years and to create a pipeline of novel cancer immunotherapeutics, many of them driven by Ohio State discoveries that will be tested at patient bedsides. To guide PIIO research efforts, the institute has organized into four interconnected centers of excellence: Cancer Immuno-Genomics, Cell Therapy, Systems Immuno-Oncology and Translational Immuno-Oncology.

Excellence in Cancer Care

The James Cancer Hospital and Solove Research Institute opened in 1990 as the Midwest’s first freestanding cancer hospital and the patient-care component of The Ohio State University Comprehensive Cancer Center. Ranked by U.S. News & World Report as one of the top hospitals in the nation for cancer care, the hospital is one of only 11 DRG-exempt (diagnosis-related-group-exempt) or PPS-exempt (prospective-payment-system-exempt) institutions in the United States.

The OSUCCC – James has helped pioneer the transdisciplinary, multimodality approach to cancer treatment and patient care. As a founding member of the National Comprehensive Cancer Network (NCCN), the OSUCCC – James helps establish national guidelines and standards of cancer care.

The OSUCCC – James has more than 200 oncologists, each of whom specializes in just one type of cancer. That expert subspecialization leads to more productive integration with cancer research and, ultimately, to better outcomes in patient care. The cancer center also offers a robust clinical trials program; many of these protocols are initiated by OSUCCC – James investigators.

Learn more about the OSUCCC – James at cancer.osu.edu.

Contact:
Dina Aziz, MSHS, Director, Clinical Trials Office
614-366-3623

Trials at this location:

BTCRC-LUN20-462

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab
as Second Line Treatment for Small Cell Lung Cancer

Status: Open to Accrual Read More

HCRN GI16-288

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Status: Closed to Accrual
Read More

HCRN GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Closed to Accrual
Read More